Developer docs
API playgroundTry for free, no card

Search company profiles

BEAM Alliance

Full company profile

uuid0037ftl

Namestring
BEAM Alliance
Legal namestring
BEAM Alliance
Company typeenum
Private
Founded yearint
2016
Descriptiontext

BEAM Alliance is a non-profit association governed by French law (law of July 1, 1901), headquartered in Lyon, France, and founded in 2016. It serves as the pan-European coalition exclusively representing approximately 69 small and medium-sized enterprises (SMEs) developing products to combat antimicrobial resistance (AMR), alongside supporting organizations in the biotechnology, pharmaceutical, and medical technology sectors. The alliance operates a member-driven go-to-market model: membership is granted through an application process requiring Board approval, and members pay annual fees (not publicly disclosed) that vary by company category and size. Members are organized into AMR-focused SMEs and Associated Organizations, with access to policy monitoring, advocacy representation, networking, event discounts, and the BEAM pipeline database.

BEAM Alliance does not develop or sell commercial products in the traditional sense. Its core offerings are organized around five standing task forces (BTF-E on Evaluation, BTF-Dx on Diagnostics, BTF-Pv on Preventive Therapies, BTF-PULL on PULL incentives, and BTF-PUSH on PUSH incentives) plus the Phage-ACT taskforce founded in March 2024. Knowledge products include the annual BeAMRometer survey (a barometer of AMR SMEs), the BEAM Pipeline Database tracking member therapeutic and diagnostic products, the BEAM Reflection Papers series, and a curated Key Reports repository. The alliance's principal technical contribution is the BEAM Infection Curve (BIC), a six-way framework developed by BTF-E for characterizing antimicrobial product activity as a roadmap for improved drug evaluation.

The alliance's value proposition is collective policy advocacy: addressing the market failure in antimicrobial R&D, fragmented national AMR policies, and regulatory barriers to SME innovation. Membership is the sole revenue stream, automatically renewed annually on a calendar-year basis (January–December). The organization has achieved tangible policy outcomes, including influencing the 2024 EU pharmaceutical legislation revision to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism, and convening a 60+ organization coalition advocating for AMR to be a G7 public health priority.

Short descriptiontext

BEAM Alliance is a non-profit association founded in 2016 and headquartered in Lyon, France, serving as the pan-European coalition of approximately 69 small and medium-sized enterprises developing products to combat antimicrobial resistance, providing advocacy, policy coordination, and networking services through membership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial resistance advocacy, SME coalition, AMR policy, pull incentives, industry association
Industry2 codes
PRIMARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
SECONDARYBPADANAB
Technical Committees, Working Groups & Expert Panels
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
NAICS code3 codes
  • Business Associations813910
  • Professional Organizations81392
  • Social Advocacy Organizations8133
SIC code1 code
  • Services-Membership Organizations8600
Product category
Industry Association / AMR Policy Advocacy
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Membership fees
TypeSubscription Recurring
Description

BEAM Alliance charges annual membership fees determined by the General Assembly. Fees vary based on company category and size, with pro rata temporis adjustments for partial-year subscriptions. Invoices are sent each year in March with 30-day payment terms. Membership automatically renews annually on a calendar-year basis (January to December). No refunds are issued for mid-year termination except at BEAM's sole discretion.

beam-alliance.eu
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details2 tiers
1Full Members — SMEs developing AMR products
ModelSubscriptionBilling cadenceAnnual
Notes

Fees vary by company size and category. Annual billing; invoices sent in March; 30-day payment terms. Pro rata adjustments for mid-year join. Automatic annual renewal January–December.

beam-alliance.eu
2Associated Organizations — supporting companies and institutions
ModelSubscriptionBilling cadenceAnnual
Notes

Fees vary by organization size and type. Same billing terms as Full Members.

beam-alliance.eu
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BEAM Alliance is a non-profit industry association that provides collective policy advocacy, regulatory monitoring, networking, and knowledge-sharing services for its SME members active in antimicrobial resistance (AMR) product development. It runs member task forces on PULL/PUSH incentives, diagnostics, prevention, evaluation, and phage therapy; publishes the annual BeAMRometer survey and reflection papers; maintains the BEAM Pipeline Database of member products; and engages EU and Member State policymakers on legislation such as the 2024 EU pharmaceutical revision.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • EU pharmaceutical legislation revised to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism for Member States
+2 more records
Product overview1 text field

BEAM Alliance is a European industry association (governed by French law of July 1, 1901) representing Small and Medium Enterprises innovating against Antimicrobial Resistance (AMR). Founded in 2016 and headquartered in Lyon, France, BEAM Alliance does not develop or sell commercial products. Instead, it provides advocacy, policy coordination, networking, and knowledge-sharing services for its member companies. The organization focuses on driving innovation in AMR prevention, diagnostics, and therapeutics through collective advocacy efforts, including publishing the annual BeAMRometer survey, facilitating policy discussions on PULL and PUSH incentives, and maintaining a pipeline database of member company AMR products under development.

Product and service2 records
1BeAMRometer (SMEs Barometer)
CategoryResearch Report
Description

Annual survey report that captures the state of innovative SMEs in the AMR field, highlighting the difficult market situation and member perceptions of the AMR innovation environment.

2BEAM Pipeline Database
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

ESCMID Global is the world's premier meeting in Clinical Microbiology and Infectious Diseases (April 17-21, 2026, Munich). BEAM Alliance collaborates with ESCMID, with BioVersys presenting data at the conference and BEAM's CEO participating in sessions on funding and policy priorities shaping AMR innovation.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

BioVersys entered a global research collaboration and exclusive license option agreement with Shionogi for the BV500 non-tuberculosis mycobacteria (NTM) program. Shionogi is listed as a signatory of the G7 AMR coalition. BioVersys is a BEAM Alliance Full Member.

3Phage-ACT (Phage Action Collaborative Taskforce)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Phage-ACT (Phage Action Collaborative Taskforce) was founded by BEAM Alliance in March 2024 to advance phage therapy and phage-derived products. It brings together academia, biotech, government, and healthcare organizations to align regulatory frameworks, establish flexible platform-based approaches, define IVD pathways, promote innovative trial designs, and align phage therapies with market access pathways.

beam-alliance.eu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ecraid is a BEAM Alliance Associated Organization developing and conducting clinical studies on infectious diseases. Listed as a key partner for AMR innovation infrastructure.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

The Microbiology Society co-organized the Therapeutics and Antimicrobial Resistance (AMR) meeting on 25 June 2026 in Manchester. BEAM Alliance promoted this event to its community.

Strategic tierMinorTypeOthers
Description

Institut Pasteur Lille is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. The coalition included BEAM Alliance, IFPMA, EFPIA, Cancer Patients Europe, and over 60 leading AMR experts.

Strategic tierMinorTypeOthers
Description

IFPMA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. James Anderson, IFPMA's Director General R&D & Innovation, chairs the AMR Industry Alliance Board.

Strategic tierMinorTypeOthers
Description

EFPIA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. Kristine Peers, EFPIA's Executive Director for Legal Affairs, is listed as a signatory.

Strategic tierMinorTypeOthers
Description

Cancer Patients Europe (CPO) is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. CEO Antonella Cardone is quoted emphasizing that AMR threatens cancer patient outcomes.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical industry federation that hosts the AMR Industry Alliance and engages on AMR policy. Comparable as an industry federation with AMR policy positions, but operates at a much broader pharma-industry level rather than an SME-focused coalition.

TypeBroad incumbent
Description

Largest US biotech industry association representing member companies across therapeutic areas including AMR. Comparable as an industry-association policy advocate for biotech SMEs, but operates at a much broader scale and US-centric scope than BEAM's pan-European AMR focus.

TypeDirect peer
Description

Public-private partnership funding early-stage antibacterial R&D (therapeutics, diagnostics, prevention) with a ~€480M portfolio. Directly comparable as a core AMR ecosystem player; CARB-X is a key funding pathway listed on BEAM's funding page and a Coalition co-signatory.

TypeDirect peer
Description

International independent network advocating for action on antibiotic resistance, working with civil society, governments, and researchers. Directly comparable as an AMR-focused advocacy coalition with a global footprint, contrasting with BEAM's European SME-industry focus.

TypeEmerging player
Description

UK-based translational AMR R&D initiative supporting SMEs and academics to advance antimicrobial candidates toward the clinic. Comparable as a sector-specialized AMR support organization focused on SMEs, but with a national UK scope rather than BEAM's pan-European advocacy mandate.

TypeDirect peer
Description

The world's largest VC fund dedicated exclusively to antimicrobial therapeutics and diagnostics, backed by major pharma. Directly comparable to BEAM Alliance as a focused AMR innovation catalyst — both address the broken antimicrobial market through coordinated action, though AMR Action Fund deploys capital while BEAM deploys policy advocacy.

TypeBroad incumbent
Description

The principal European pharmaceutical industry federation, representing large-pharma members including those working on AMR. Comparable as an EU policy advocacy organization for pharma, but EFPIA operates as a broader industry association with AMR as one of many topics — making it a broader incumbent whose AMR positions BEAM must navigate.

8Antibiotic Resistance Coalition (ARC)
TypeDirect peer
Description

Civil-society coalition working on antibiotic resistance policy and access. Directly comparable as a multi-stakeholder AMR advocacy coalition, though more public-interest and access-focused than BEAM's SME-industry positioning.

9AMR Industry Alliance
TypeDirect peer
Description

Industry-led coalition of pharma, biotech, diagnostics, and generics companies committed to addressing AMR. Directly comparable as an AMR-focused advocacy coalition, though its membership skews toward large-pharma signatories versus BEAM's SME-only focus.

TypeDirect peer
Description

Non-profit drug developer focused on new antibiotics for public health priorities; a BEAM Associated Organization member. Directly comparable in mission (sustaining antibiotic R&D against market failure) but operates as a product developer rather than a coalition advocate, making GARDP a peer rather than a competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BEAM Alliance

Industry Association / AMR Policy Advocacybeam-alliance.eu

BEAM Alliance is a non-profit association founded in 2016 and headquartered in Lyon, France, serving as the pan-European coalition of approximately 69 small and medium-sized enterprises developing products to combat antimicrobial resistance, providing advocacy, policy coordination, and networking services through membership.

What BEAM Alliance does

BEAM Alliance is a non-profit association governed by French law (law of July 1, 1901), headquartered in Lyon, France, and founded in 2016. It serves as the pan-European coalition exclusively representing approximately 69 small and medium-sized enterprises (SMEs) developing products to combat antimicrobial resistance (AMR), alongside supporting organizations in the biotechnology, pharmaceutical, and medical technology sectors. The alliance operates a member-driven go-to-market model: membership is granted through an application process requiring Board approval, and members pay annual fees (not publicly disclosed) that vary by company category and size. Members are organized into AMR-focused SMEs and Associated Organizations, with access to policy monitoring, advocacy representation, networking, event discounts, and the BEAM pipeline database.

BEAM Alliance does not develop or sell commercial products in the traditional sense. Its core offerings are organized around five standing task forces (BTF-E on Evaluation, BTF-Dx on Diagnostics, BTF-Pv on Preventive Therapies, BTF-PULL on PULL incentives, and BTF-PUSH on PUSH incentives) plus the Phage-ACT taskforce founded in March 2024. Knowledge products include the annual BeAMRometer survey (a barometer of AMR SMEs), the BEAM Pipeline Database tracking member therapeutic and diagnostic products, the BEAM Reflection Papers series, and a curated Key Reports repository. The alliance's principal technical contribution is the BEAM Infection Curve (BIC), a six-way framework developed by BTF-E for characterizing antimicrobial product activity as a roadmap for improved drug evaluation.

The alliance's value proposition is collective policy advocacy: addressing the market failure in antimicrobial R&D, fragmented national AMR policies, and regulatory barriers to SME innovation. Membership is the sole revenue stream, automatically renewed annually on a calendar-year basis (January–December). The organization has achieved tangible policy outcomes, including influencing the 2024 EU pharmaceutical legislation revision to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism, and convening a 60+ organization coalition advocating for AMR to be a G7 public health priority.

BEAM Alliance firmographics

Firmographics
Name
BEAM Alliance
Legal name
BEAM Alliance
Website
https://beam-alliance.eu
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
BEAM Alliance is a non-profit association founded in 2016 and headquartered in Lyon, France, serving as the pan-European coalition of approximately 69 small and medium-sized enterprises developing products to combat antimicrobial resistance, providing advocacy, policy coordination, and networking services through membership.
Ownership category
akta.pro rank

BEAM Alliance industry classification

Industry
Product category
Industry Association / AMR Policy Advocacy
NAICS
Business Associations (813910), Professional Organizations (81392), Social Advocacy Organizations (8133)
SIC
Services-Membership Organizations (8600)
akta.pro industry
PRIMARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
SECONDARYBPADANAB
Technical Committees, Working Groups & Expert Panels
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

  • Antimicrobial resistance advocacy
  • SME coalition
  • AMR policy
  • Pull incentives
  • Industry association

Where BEAM Alliance is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

BEAM Alliance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Membership fees: BEAM Alliance charges annual membership fees determined by the General Assembly. Fees vary based on company category and size, with pro rata temporis adjustments for partial-year subscriptions. Invoices are sent each year in March with 30-day payment terms. Membership automatically renews annually on a calendar-year basis (January to December). No refunds are issued for mid-year termination except at BEAM's sole discretion.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualFull Members — SMEs developing AMR products
SubscriptionAnnualAssociated Organizations — supporting companies and institutions

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

BEAM Alliance product offering

Product offering

Core offering

BEAM Alliance is a non-profit industry association that provides collective policy advocacy, regulatory monitoring, networking, and knowledge-sharing services for its SME members active in antimicrobial resistance (AMR) product development. It runs member task forces on PULL/PUSH incentives, diagnostics, prevention, evaluation, and phage therapy; publishes the annual BeAMRometer survey and reflection papers; maintains the BEAM Pipeline Database of member products; and engages EU and Member State policymakers on legislation such as the 2024 EU pharmaceutical revision.

Product overview

BEAM Alliance is a European industry association (governed by French law of July 1, 1901) representing Small and Medium Enterprises innovating against Antimicrobial Resistance (AMR). Founded in 2016 and headquartered in Lyon, France, BEAM Alliance does not develop or sell commercial products. Instead, it provides advocacy, policy coordination, networking, and knowledge-sharing services for its member companies. The organization focuses on driving innovation in AMR prevention, diagnostics, and therapeutics through collective advocacy efforts, including publishing the annual BeAMRometer survey, facilitating policy discussions on PULL and PUSH incentives, and maintaining a pipeline database of member company AMR products under development.

Differentiator

Problem solved

Functional benefit

Products and services

  • BeAMRometer (SMEs Barometer) Annual survey report that captures the state of innovative SMEs in the AMR field, highlighting the difficult market situation and member perceptions of the AMR innovation environment.
  • BEAM Pipeline Database

Quantifiable outcome

  • EU pharmaceutical legislation revised to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism for Member States
  • +2 more outcomes

Companies that use BEAM Alliance

Customer profile

Segments4 records

Ideal customer profiles3 records

BEAM Alliance technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BEAM Alliance partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • ESCMID (European Society of Clinical Microbiology and Infectious Diseases)coreStrategic or Co-development Partner · 17 April 2026ESCMID Global is the world's premier meeting in Clinical Microbiology and Infectious Diseases (April 17-21, 2026, Munich). BEAM Alliance collaborates with ESCMID, with BioVersys presenting data at the conference and BEAM's CEO participating in sessions on funding and policy priorities shaping AMR innovation.
  • Shionogi & Co., Ltd.majorStrategic or Co-development Partner · 16 April 2026BioVersys entered a global research collaboration and exclusive license option agreement with Shionogi for the BV500 non-tuberculosis mycobacteria (NTM) program. Shionogi is listed as a signatory of the G7 AMR coalition. BioVersys is a BEAM Alliance Full Member.
  • Phage-ACT (Phage Action Collaborative Taskforce)coreStrategic or Co-development Partner · 1 March 2024Phage-ACT (Phage Action Collaborative Taskforce) was founded by BEAM Alliance in March 2024 to advance phage therapy and phage-derived products. It brings together academia, biotech, government, and healthcare organizations to align regulatory frameworks, establish flexible platform-based approaches, define IVD pathways, promote innovative trial designs, and align phage therapies with market access pathways.
  • ecraid (European Clinical Research Alliance on Infectious Diseases)coreStrategic or Co-development Partnerecraid is a BEAM Alliance Associated Organization developing and conducting clinical studies on infectious diseases. Listed as a key partner for AMR innovation infrastructure.
  • Microbiology SocietyminorStrategic or Co-development PartnerThe Microbiology Society co-organized the Therapeutics and Antimicrobial Resistance (AMR) meeting on 25 June 2026 in Manchester. BEAM Alliance promoted this event to its community.
  • Institut Pasteur LilleminorOthersInstitut Pasteur Lille is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. The coalition included BEAM Alliance, IFPMA, EFPIA, Cancer Patients Europe, and over 60 leading AMR experts.
  • IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)minorOthersIFPMA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. James Anderson, IFPMA's Director General R&D & Innovation, chairs the AMR Industry Alliance Board.
  • EFPIA (European Federation of Pharmaceutical Industries and Associations)minorOthersEFPIA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. Kristine Peers, EFPIA's Executive Director for Legal Affairs, is listed as a signatory.
  • Cancer Patients EuropeminorOthersCancer Patients Europe (CPO) is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. CEO Antonella Cardone is quoted emphasizing that AMR threatens cancer patient outcomes.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

BEAM Alliance competitors and assessment

Company assessment

Broad incumbents

  • IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): Global pharmaceutical industry federation that hosts the AMR Industry Alliance and engages on AMR policy. Comparable as an industry federation with AMR policy positions, but operates at a much broader pharma-industry level rather than an SME-focused coalition.
  • BIO (Biotechnology Innovation Organization): Largest US biotech industry association representing member companies across therapeutic areas including AMR. Comparable as an industry-association policy advocate for biotech SMEs, but operates at a much broader scale and US-centric scope than BEAM's pan-European AMR focus.
  • EFPIA (European Federation of Pharmaceutical Industries and Associations): The principal European pharmaceutical industry federation, representing large-pharma members including those working on AMR. Comparable as an EU policy advocacy organization for pharma, but EFPIA operates as a broader industry association with AMR as one of many topics — making it a broader incumbent whose AMR positions BEAM must navigate.

Direct peers

  • CARB-X: Public-private partnership funding early-stage antibacterial R&D (therapeutics, diagnostics, prevention) with a ~€480M portfolio. Directly comparable as a core AMR ecosystem player; CARB-X is a key funding pathway listed on BEAM's funding page and a Coalition co-signatory.
  • ReAct: International independent network advocating for action on antibiotic resistance, working with civil society, governments, and researchers. Directly comparable as an AMR-focused advocacy coalition with a global footprint, contrasting with BEAM's European SME-industry focus.
  • AMR Action Fund: The world's largest VC fund dedicated exclusively to antimicrobial therapeutics and diagnostics, backed by major pharma. Directly comparable to BEAM Alliance as a focused AMR innovation catalyst — both address the broken antimicrobial market through coordinated action, though AMR Action Fund deploys capital while BEAM deploys policy advocacy.
  • Antibiotic Resistance Coalition (ARC): Civil-society coalition working on antibiotic resistance policy and access. Directly comparable as a multi-stakeholder AMR advocacy coalition, though more public-interest and access-focused than BEAM's SME-industry positioning.
  • AMR Industry Alliance: Industry-led coalition of pharma, biotech, diagnostics, and generics companies committed to addressing AMR. Directly comparable as an AMR-focused advocacy coalition, though its membership skews toward large-pharma signatories versus BEAM's SME-only focus.
  • GARDP (Global Antibiotic Research & Development Partnership): Non-profit drug developer focused on new antibiotics for public health priorities; a BEAM Associated Organization member. Directly comparable in mission (sustaining antibiotic R&D against market failure) but operates as a product developer rather than a coalition advocate, making GARDP a peer rather than a competitor.

Emerging players

  • AMR Centre (UK): UK-based translational AMR R&D initiative supporting SMEs and academics to advance antimicrobial candidates toward the clinic. Comparable as a sector-specialized AMR support organization focused on SMEs, but with a national UK scope rather than BEAM's pan-European advocacy mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BEAM Alliance social profiles

Digital presence

BEAM Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BEAM Alliance leadership team

Management profile

Number of profiles

Profiles10 records

BEAM Alliance funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BEAM Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BEAM Alliance

What does BEAM Alliance do?

BEAM Alliance is a non-profit industry association that provides collective policy advocacy, regulatory monitoring, networking, and knowledge-sharing services for its SME members active in antimicrobial resistance (AMR) product development. It runs member task forces on PULL/PUSH incentives, diagnostics, prevention, evaluation, and phage therapy; publishes the annual BeAMRometer survey and reflection papers; maintains the BEAM Pipeline Database of member products; and engages EU and Member State policymakers on legislation such as the 2024 EU pharmaceutical revision.

Is BEAM Alliance a public or private company?

BEAM Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was BEAM Alliance founded?

BEAM Alliance was founded in 2016. It employs 1 to 10 people.

Where is BEAM Alliance based?

BEAM Alliance is headquartered in Lyon, France, in the Europe region.

How does BEAM Alliance make money?

One revenue line is on record: membership fees.

Who are BEAM Alliance's main competitors?

Broad incumbents on record are IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), BIO (Biotechnology Innovation Organization) and EFPIA (European Federation of Pharmaceutical Industries and Associations). Direct peers are CARB-X, ReAct, AMR Action Fund, Antibiotic Resistance Coalition (ARC), AMR Industry Alliance and GARDP (Global Antibiotic Research & Development Partnership). AMR Centre (UK) is listed as an emerging player.

Does BEAM Alliance have an API?

No public API is recorded for BEAM Alliance.

What industry is BEAM Alliance in?

BEAM Alliance's product category is Industry Association / AMR Policy Advocacy. Its primary akta.pro industry code is BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation, with a secondary code of BPADANAB, Technical Committees, Working Groups & Expert Panels. Its NAICS code is 813910 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales